Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Friday.

TRVI has been the subject of several other research reports. HC Wainwright started coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They set a "buy" rating and a $21.00 price target for the company. B. Riley reiterated a "buy" rating and set a $20.00 target price (up previously from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a report on Monday. Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price objective for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Finally, D. Boral Capital reissued a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Monday. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $18.63.

Trevi Therapeutics Stock Performance

TRVI stock traded up $0.32 during trading on Friday, reaching $7.06. 2,488,937 shares of the company were exchanged, compared to its average volume of 1,321,988. The stock's 50 day moving average price is $6.26 and its 200 day moving average price is $4.99. Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.48. The company has a market cap of $705.24 million, a P/E ratio of -16.05 and a beta of 0.59.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. As a group, equities research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Transactions at Trevi Therapeutics

In related news, CEO Jennifer L. Good sold 5,263 shares of the firm's stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the transaction, the chief executive officer now owns 213,313 shares in the company, valued at approximately $1,403,599.54. This trade represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. This trade represents a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 18.30% of the company's stock.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its position in shares of Trevi Therapeutics by 14.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock worth $713,000 after buying an additional 22,145 shares in the last quarter. Renaissance Technologies LLC raised its stake in Trevi Therapeutics by 42.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock worth $414,000 after acquiring an additional 29,700 shares during the period. American Century Companies Inc. lifted its holdings in shares of Trevi Therapeutics by 44.7% in the 4th quarter. American Century Companies Inc. now owns 78,143 shares of the company's stock worth $322,000 after purchasing an additional 24,153 shares during the last quarter. Northern Trust Corp grew its stake in Trevi Therapeutics by 11.3% during the 4th quarter. Northern Trust Corp now owns 482,815 shares of the company's stock worth $1,989,000 after buying an additional 49,173 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Trevi Therapeutics by 187.0% in the fourth quarter. Ameriprise Financial Inc. now owns 96,784 shares of the company's stock valued at $399,000 after buying an additional 63,067 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.